Cognition Therapeutics, Inc. logo

Cognition Therapeutics, Inc.

NASDAQ:CGTX

Overview | Financials
Company Name Cognition Therapeutics, Inc.
Symbol CGTX
Currency USD
Price 0.6
Market Cap 24,083,789
Dividend Yield 0%
52-week-range 0.542 - 2.95
Industry Biotechnology
Sector Healthcare
CEO Ms. Lisa Ricciardi
Website https://www.cogrx.com

An error occurred while fetching data.

About Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment

Related Stocks

ReWalk Robotics Ltd. logo

ReWalk Robotics Ltd.

RWLK

1.05 USD

Solid Biosciences Inc. logo

Solid Biosciences Inc.

SLDB

7.93 USD

MediWound Ltd. logo

MediWound Ltd.

MDWD

17.69 USD

Medicenna Therapeutics Corp. logo

Medicenna Therapeutics Corp.

MDNA

0.157 USD

Financials

Numbers are in millions USD

Numbers are in millions USD